ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 223

Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study

Osamu Ishida1, Takefumi Furuya2, Eisuke Inoue3, Kensuke Ochi2, Katsunori Ikari2, Atsuo Taniguchi4, Hisashi Yamanaka2 and Shigeki Momohara4, 1Orthopedics, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 3Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Fracture risk, Japanese, prednisolone, prednisone, rheumatoid arthritis (RA) and spine involvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and Diagnosis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing vertebral fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort study, we reported clinical risk factors for clinicalvertebral fractures in Japanese patients with RA. However, in our previous studies, which analyzed data from 2000 to 2005, the number of patients with verified clinical vertebral fractures was only 40. The aim of this study was to re-evaluate the associations between potential risk factors and the occurrence of clinical vertebral fractures in a larger number of Japanese patients with RA.

Methods: IORRA is a prospective observational cohort study of Japanese patients with RA established in 2000 at the Institute of Rheumatology, Tokyo Women’s Medical University. A total of 10,240 Japanese patients with RA  (82% female; mean age, 56 years) were enrolled in IORRA cohort study from 2000 to 2011. Self-reported vertebral fractures were verified with patient medical records and radiographs. Independent contributions of various risk factors to clinical vertebral fracture occurrence were analyzed with Cox proportional hazards models.

Results: During a mean follow-up of 4.9 years, 399 patients reported 638 clinical vertebral fractures. Among these patients, 187 clinical vertebral fractures in 187 patients (18 men, 169 women) were verified with medical records (n = 95) and radiographs (n =92). The vertebral fractures were mainly caused by spontaneous events (65%) and falls (25%). Vertebral fractures occurred at lumbar (36%), thoracic (37%), and both (27%) levels of the spine. In men with RA, multivariate Cox regression analyses estimated that the risk of sustaining a clinical vertebral fracture increased by 2.51 for every 10 years of increased age, 2.96 for Japanese version of Health Assessment Questionnaire-Disability Index (J-HAQ-DI), and 1.17 for daily prednisolone dose (Table 1). In women with RA, multivariate Cox regression analyses estimated that the risk of sustaining a clinical vertebral fracture increased by 1.30 for Disease Activity Score 28 (DAS28), 2.35 for history of any previous fractures, 1.67 for every 10 years of increased age, 1.39 for J-HAQ-DI, and 1.08 for daily prednisolone dose (Table 1). Among the eight domains of the J-HAQ-DI, J-HAQ-DI (arising) was significantly associated with the clinical vertebral fractures in Japanese patients with RA (hazard ratio 1.26, 95% confidence interval [CI] 1.02-1.54).

Conclusion: We confirmed the associations between clinical vertebral fractures and advanced age, J-HAQ-DI, and high daily prednisolone dose in a larger number of patients and found significant correlations between clinical vertebral fractures and DAS28, history of any previous fractures, and J-HAQ-DI (arising) in Japanese patients with RA. These clinical risk factors  appear to be different between men and women in Japanese RA patients.

Table 1. Hazard ratios (95% confidence interval) for the occurrence of clinical vertebral fractures in Japanese men and women with RA: Multivariate analyses.
Risk factors Men Women
DAS28 0.73 (0.36-2.48) 1.30 (1.05-1.63)
History of any prior fracture 1.32 (0.45-3.81) 2.35 (1.69-3.27)
Age, per 10 years 2.51 (1.34-4.73) 1.67 (1.42-1.97)
Japanese HAQ-DI 2.96 (1.02-3.60) 1.39 (1.08-1.79)
Daily prednisolone dose, mg/day 1.17 (1.06-1.29) 1.08 (1.05-1.12)

Disclosure:

O. Ishida,
None;

T. Furuya,
None;

E. Inoue,
None;

K. Ochi,
None;

K. Ikari,
None;

A. Taniguchi,
None;

H. Yamanaka,

Abbott, AbbVie, Asahikasei , Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taishotoyama, Takeda, Teijin,,

2,

Abbott, AbbVie, Astellas, AstraZeneca, Bristol-Myers Squib, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, Takeda, Teijin,

5,

Abbott, AbbVie, Astellas, Bristol-Myers Squib, Chugai, Eisai, Mitsubishi Tanabe, Pfizer, Takeda, Teijin,

8;

S. Momohara,

Abbvie Japan, Chugai Parmaceutical, Eisai, Mitsubishi Tanabe Parma, Takeda Parmaceutical,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-clinical-vertebral-fractures-in-japanese-men-and-women-with-rheumatoid-arthritis-results-from-a-large-prospective-observational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology